The evidence behind the plasma platform
PlasmaDrive™ is formulated on a spray-dried plasma platform, supported by peer-reviewed research across canine, equine, and livestock nutrition. This page presents that evidence the way you would review it: what each study measured, what it supports — and what it does not.
Six bodies of evidence, weighed honestly
Not all evidence carries the same weight for a joint claim. Select a category to see exactly what it supports — and where it stops.
Bar length reflects the weight of each category for a canine joint claim specifically — an editorial judgement, not a statistic.
Canine plasma — joint & OA
Dietary spray-dried plasma improved lameness scoring, inflammatory indicators, and joint biomarkers in senior dogs with diagnosed osteoarthritis (Sun 2026) — the peer-reviewed result the platform is built on.
One controlled trial, at roughly ten times the PlasmaDrive chew dose, with APC co-authorship. One trial is not “clinically proven.”
UC-II® head-to-head vs glucosamine
In head-to-head canine trials, UC-II outperformed glucosamine + chondroitin on both owner-reported scoring and objective force-plate measurement (D’Altilio 2007; Gupta 2012).
The percentages belong to UC-II at trial doses in those trials — they do not transfer to the PlasmaDrive formula as a whole.
Canine plasma — gut, digestibility & immune
Dogs accept plasma, digest it well, and respond favourably on gut, microbiota, and immune measures (Mioto 2025, U. of Illinois; Quigley 2004).
Neither is a joint study. Research Beagles, not client-owned patients.
Equine plasma — gait & inflammation
Orally administered plasma proteins reached a systemic inflammatory endpoint and an objective movement measure in 27 mature horses (Fikes 2021, Texas A&M). The only other species with a movement endpoint.
Different species, different dose scale (40–80 g/day), different endpoint. Context for the mechanism, not canine evidence.
Gut barrier, immune & mechanism
Controlled rodent work explains how oral plasma lowers systemic inflammatory tone: reduced pathogen binding, barrier integrity, modulated cytokine expression (Pérez-Bosque series; Miró 2017).
Explains how, not whether, in a target species. Mouse cognition data is never presented as a canine benefit.
Livestock plasma — swine & cattle feed
Three decades and hundreds of controlled studies establish safety at scale and an IgG-mediated gut mechanism, including an independent meta-analysis (Balan 2021, Massey University).
Not joint evidence. Any “hundreds of studies” line attaches to safety and mechanism — never to joint benefit.
The anchor: one randomised controlled trial
This is the entire canine joint-specific plasma literature to date. It is a real, positive, peer-reviewed result — and it is one trial, at a dietary dose. Both halves of that sentence matter.
Randomised controlled feeding trial. Twenty-four dogs over seven years of age, each with osteoarthritis diagnosed on both radiographic evidence and clinical signs, in two groups of twelve. Treatment received the basal diet with spray-dried animal plasma at 4% inclusion replacing chicken meal. Forty-two days.
Improvement in lameness scoring alongside favourable shifts in inflammatory indicators, antioxidant capacity, and joint-relevant biomarkers including matrix metalloproteinase activity. Benefit reached significance at day 42 rather than the earlier timepoint.
That dietary spray-dried plasma can improve clinical signs and joint biomarkers in dogs with diagnosed OA. A real, positive, peer-reviewed result — the reason the platform exists.
Any claim at the PlasmaDrive chew dose. Trial exposure (~28 g/day) is roughly an order of magnitude above a commercial chew serving. A single trial with industry co-authorship is not “clinically proven.”
Authorship disclosure. APC personnel are co-authors. University partner: China Agricultural University, Beijing.
Dogs accept it, digest it, and respond on gut and immune measures
Two studies carry the safety, palatability, and whole-body-health story. Neither is a joint study, and neither is presented as one.
Twelve adult Beagles in a replicated Latin square across four dietary treatments: control; 4% plasma as a kibble coating; and 4% or 8% plasma in the kibble matrix before extrusion. Swine-derived plasma partially replaced chicken meal; extrusion parameters were also evaluated.
Plasma inclusion influenced nutrient digestibility and modulated gut microbiota, with meaningful shifts in faecal metabolite profiles indicating a beneficial microbial effect. Serum chemistry and immune and inflammatory biomarkers were assessed alongside.
Gut-health and digestibility positioning, and the whole-body framing of the platform — from a US university animal science department.
Any joint or mobility claim. This study did not measure joints. Research Beagles, not client-owned patients.
Authorship disclosure. University of Illinois Urbana-Champaign, Department of Animal Sciences, with APC co-authorship.
Feeding study in Beagles evaluating dietary spray-dried animal plasma at 2% inclusion against control, measuring voluntary intake and apparent nutrient digestibility.
Plasma inclusion significantly improved dry-matter and crude-fibre digestibility and was highly palatable — dogs readily consumed plasma-containing diets.
Baseline safety, acceptance, and nutritional value. The palatability finding is commercially meaningful for a chew format.
Joint, mobility, or anti-inflammatory claims.
Authorship disclosure. All four authors are APC personnel; no university partner. Used for palatability and digestibility, not as an independence signal.
How an oral protein reaches a joint outcome
The question a veterinarian asks first: by what mechanism would a blood-derived protein fed by mouth affect a joint? Plasma acts systemically on inflammation and the gut barrier — not locally on cartilage. Step through the pathway.
Spray-drying preserves a bioactive protein fraction
Spray-dried plasma retains functional proteins: immunoglobulins (principally IgG), albumin, transferrin, growth factors, and bioactive peptides. This fraction — not amino-acid nutrition — is what gives the ingredient a defined biological job.
Evidence. Composition characterised in an independent review (Kazimierska 2023, open access): immunoglobulins, albumin, growth factors, peptides, transferrin, and enzymes.
IgG acts at the gut wall
Fed orally, the IgG-rich fraction acts at the intestinal mucosa: it reduces pathogen binding to the gut wall and supports barrier integrity. This is the mechanism behind three decades of swine post-weaning data.
Evidence. Balan 2021 meta-analysis attributes the livestock effect substantially to IgG preventing pathogen binding; Pérez-Bosque rodent series (2004–2010) shows improved barrier function.
Local response becomes systemic
Modulating the mucosal immune response lowers pro-inflammatory cytokine expression beyond the gut. In mature horses, oral plasma proteins reached serum TNF-α and IL-1β alongside an objective gait endpoint — evidence the signal is systemic in a large athletic mammal.
Evidence. Fikes 2021 (Texas A&M, randomised, 27 horses, open access): gait kinematics and systemic inflammatory cytokines over 34 days at 40–80 g/day.
Lower inflammatory tone, not cartilage substrate
Chronic low-grade inflammation is a principal driver of osteoarthritic pain and progression — not merely a consequence of mechanical wear. A systemic reduction in inflammatory tone is therefore a plausible route to joint comfort that does not require the ingredient to reach the joint as a structural substrate. That is a genuinely different mechanism from glucosamine.
Evidence. The canine test of this chain is Sun 2026: lameness scoring, inflammatory indicators, and MMP activity all moved together at dietary dose over 42 days.
Oral spray-dried plasma (SDP) and injectable platelet-rich plasma (PRP) are entirely different products, with separate evidence bases and separate regulatory status. Everything on this page concerns oral SDP as a dietary ingredient — nothing here relates to PRP therapy.
The dose gap, shown rather than hidden
The canine joint trial fed plasma at roughly 4% of the diet — on the order of 28 g/day. No chew on the market delivers that. PlasmaDrive is informed by this literature, not proven by it; PlasmaDrive Pro narrows the gap during loading, and whether that matters is what the Phoenix Bioscience observational pilot is designed to find out.
Trial exposure is approximate, scaled from the dogs studied. PlasmaDrive Pro loading intake ranges 12,500–17,500 mg/day by weight tier — the only configuration in the category that approaches study-level exposure. Whether loading accelerates or amplifies response is a hypothesis under test in the Phoenix Bioscience observational pilot (PBX-PF-002), not an established finding.
The strongest comparative data in the formula
Unlike everything else on this page, the UC-II comparison rests on direct head-to-head trials in dogs — the same animals, the same protocol. It is why UC-II is the one branded active remaining in PlasmaDrive.
Days on supplement before improvement reached statistical significance, each in its own randomised canine trial (scale 0–120 days).
Significant reduction in overall pain by day 30; maximum effect at day 120. All groups relapsed after a 30-day withdrawal.
In the canonical randomised canine trial, glucosamine/chondroitin did not reach significance until approximately day 70 — markedly slower onset than the NSAID control arm.
UC-II®
Greater improvement than glucosamine + chondroitin on both subjective pain scoring and objective ground-force-plate measurement, with no safety signals on organ-function monitoring (Gupta 2012, Murray State University).
Glucosamine / chondroitin
In block-randomised, double-blind, placebo-controlled force-plate testing across 75 dogs, glucosamine/chondroitin did not separate from placebo on peak vertical force (Kampa 2023). Two systematic reviews judge the evidence weak (Barbeau-Grégoire 2022; Vandeweerd 2012).
Force plate is the objective endpoint canine OA sceptics respect. The glucosamine literature is mixed rather than uniformly negative — the defensible framing is slow onset and objectively unproven, with citations. Not “glucosamine doesn’t work.”
Dosing disclosure. The canine clinical dose of UC-II® is 40 mg/day. PlasmaDrive delivers 40 mg/day at the 40–99 lb two-chew tier and above; dogs under 40 lb receive 20 mg/day. Trial percentages belong to the cited studies and their doses — they are not PlasmaDrive outcomes.
Arthritic dogs in four groups: control; UC-II alone (10 mg/day); glucosamine HCl 2,000 mg + chondroitin sulfate 1,600 mg; and the combination. Daily dosing for 120 days, then a 30-day withdrawal. Pain and lameness graded 0–4 at rest, on limb manipulation, and after exercise.
UC-II alone significantly reduced overall pain within 30 days (33%); pain on limb manipulation and exercise-associated lameness by day 60 (66% and 44%). Maximum reductions at day 120: 62% overall pain, 91% on manipulation, 78% exercise-associated lameness. All treated groups relapsed after withdrawal.
A within-trial comparison showing UC-II outperforming glucosamine + chondroitin in the same dogs under the same protocol, with a 30-day onset.
Transfer of these percentages to PlasmaDrive — they belong to this trial and this dosing. The control group was untreated rather than placebo-controlled.
Client-owned moderately arthritic dogs. Two objectives: efficacy of UC-II alone or combined with glucosamine hydrochloride and chondroitin sulphate, and tolerability. Pain assessed by ground force plate — an objective, instrument-based measure — alongside subjective scoring, with organ-function safety monitoring.
UC-II produced greater improvement than glucosamine + chondroitin on both subjective pain scoring and objective force-plate measurement. No safety signals on organ-function monitoring.
The most valuable form of the claim: force plate is the endpoint canine OA sceptics respect — and the same endpoint on which glucosamine failed to beat placebo (Kampa 2023).
Claims at PlasmaDrive's small-dog dose. The canine clinical dose is 40 mg/day, delivered at the 40–99 lb two-chew tier and above; dogs under 40 lb receive 20 mg/day.
Stabile compared UC-II against robenacoxib, a veterinary NSAID, using LOAD and mobility scoring over 30 days. Deparle established the 90-day response profile of glycosylated undenatured type-II collagen. Varney examined UC-II in exercising dogs.
In the Stabile work, UC-II and robenacoxib produced improvements of similar magnitude in LOAD and mobility scores between baseline and day 30 (approximately 31.5% and 32.7%). Deparle found greatest physical improvement at 90 days of daily dosing.
Breadth and consistency of the UC-II canine literature, including a published trial where UC-II improved mobility to a degree comparable with a prescription veterinary NSAID over 30 days.
Any statement that PlasmaDrive is equivalent to, or a substitute for, an NSAID. That is a drug claim and cannot appear in any form.
The full source list
Every study cited on this page, grouped by evidence category. Filter to the category you want to check.
PlasmaDrive™ is a dietary supplement that supports normal inflammatory balance, joint comfort, and mobility. It is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for veterinary care or prescription anti-inflammatories. Studies cited on this page evaluated the ingredients and doses described in each trial — not the PlasmaDrive formula. PlasmaDrive™, GutDrive™, and HydraDrive™ are trademarks of Phoenix Bioscience. UC-II® is a registered trademark of Lonza.